ORIC PHARMACEUTICALS, INC. Additional Paid in Capital, Common Stock
ORIC PHARMACEUTICALS, INC. (ORIC) had Additional Paid in Capital, Common Stock of $1.15 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-03
- 2026-06-30: Additional Paid in Capital, Common Stock $1.15B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.14B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.08B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.07B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $1.15B 10-Q · filed 2026-08-03 |
| 2026-03-31 | $1.14B 10-Q · filed 2026-05-04 |
| 2025-12-31 | $1.08B 10-Q · filed 2026-08-03 |
| 2025-09-30 | $1.07B 10-Q · filed 2025-11-13 |
| 2025-06-30 | $952.95M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $812.32M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $805.51M 10-K · filed 2026-02-23 |
| 2024-09-30 | $799.73M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $794.55M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $788.74M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $658.75M 10-K · filed 2025-02-18 |
| 2023-09-30 | $654.37M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $650.48M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $561.48M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $557.87M 10-K · filed 2024-03-11 |
| 2022-09-30 | $529.95M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $526.65M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $522.14M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $518.18M 10-K · filed 2023-03-16 |
| 2021-09-30 | $513.87M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $462.23M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $458.96M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $456.20M 10-K · filed 2022-03-21 |
| 2020-09-30 | $322.54M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $307.83M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $3.15M 10-Q · filed 2020-05-20 |
| 2019-12-31 | $2.61M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |